Hidetaka Kawabata
Overview
Explore the profile of Hidetaka Kawabata including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
40
Citations
373
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Sasagasako N, Aoki-Kamiya C, Tada Y, Miyake T, Maezawa T, Kawabata H, et al.
J Obstet Gynaecol Res
. 2025 Feb;
51(3):e16252.
PMID: 40015319
Aim: The number of childhood or adolescent and young adult cancer survivors is increasing. Often, they encounter new problems, such as late complications after cancer treatment and pregnancy. Female cancer...
2.
Fujimoto A, Ikeda K, Kinowaki K, Ogura T, Takeiwa T, Kawabata H, et al.
Pathol Int
. 2025 Feb;
75(2):92-99.
PMID: 39936817
We previously reported that strong immunoreactivity (IR) of estrogen-responsive finger protein (Efp), also known as tripartite motif-containing 25 (TRIM25), predicts poor prognosis in patients with estrogen receptor-positive and -negative invasive...
3.
Endo Y, Kotani H, Tamura N, Tanaka K, Kudo C, Sawaki M, et al.
Breast Cancer
. 2024 Sep;
31(6):1130-1136.
PMID: 39312110
Background: Tailored axillary surgery (TAS) is a new approach for selective removal of metastatic lymph nodes. This study evaluated the safety and utility of TAS using a breast biopsy clip...
4.
Shibata A, Tamura N, Kinowaki K, Nishikawa A, Tanaka K, Kobayashi Y, et al.
Breast Cancer
. 2024 Jul;
31(6):1018-1027.
PMID: 39020239
Background: Chemotherapy is crucial for hormone receptor-positive, human epidermal growth factor receptor 2 (HER2)-negative breast cancer, and its survival benefits may outweigh adverse events. Oncotype DX (ODX) assesses this balance;...
5.
6.
Reliability and validity of the Japanese version of the Chemotherapy-induced Alopecia Distress Scale
Aoyama Y, Hoshino E, Shimomura A, Shimizu C, Taniyama T, Tada M, et al.
Breast Cancer
. 2023 Dec;
31(2):234-242.
PMID: 38079066
Background: The Chemotherapy-induced Alopecia Distress Scale (CADS) is a patient-reported outcome measure for assessing distress associated with Chemotherapy-induced alopecia (CIA). This study aimed to confirm the psychometric validity of the...
7.
Ozaki Y, Kinowaki K, Kawabata H, Kudo-Saito C
Am J Cancer Res
. 2023 Nov;
13(10):4931-4943.
PMID: 37970362
Recurrence and metastasis are resistant to multimodal treatments, and are the major causes of death in breast cancer. Accumulating evidence suggests that the IL17RB signaling pathway plays a key role...
8.
Masuda J, Sakai H, Tsurutani J, Tanabe Y, Masuda N, Iwasa T, et al.
J Immunother Cancer
. 2023 Sep;
11(9).
PMID: 37709297
Background: Hormone receptor (HR)-positive breast cancer is a disease for which no immune checkpoint inhibitors have shown promise as effective therapies. Cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitors synergistically increased...
9.
Kawaguchi S, Tamura N, Suzuki S, Nishikawa A, Shibata A, Tanaka K, et al.
Jpn J Clin Oncol
. 2023 Apr;
53(7):562-571.
PMID: 37057634
Objective: We occasionally observed internal mammary lymph node metastases of breast cancer in a clinical setting. However, unlike a standard treatment in axillary metastasis, surgical resection for internal mammary lymph...
10.
Kawaguchi S, Kinowaki K, Tamura N, Masumoto T, Nishikawa A, Shibata A, et al.
Breast Cancer
. 2023 Apr;
30(4):637-646.
PMID: 37020090
Background: Invasive lobular carcinoma (ILC) grows diffusely in a single-cell fashion, sometimes presenting only subtle changes in preoperative imaging; therefore, axillary lymph node (ALN) metastases of ILC are difficult to...